StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (CAI) stock

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.94−1.06 (-5.05%)

Close on Nov 17, 2026Market cap $5.63BP/E –Yield –

Caris Life Sciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Caris Life Sciences's total debt was $393.27M at Sep 30, 2026. For fiscal 2025 it was $378.99M, down 0.1% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$378.99M-0.1%
FY2024Dec 31, 2024$379.53M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$393.27M+4.5%
Q2 FY2026Jun 30, 2026$393.15M+5.2%
Q1 FY2026Mar 31, 2026$381.58M+0.5%
Q4 FY2025Dec 31, 2025$378.99M–
Q3 FY2025Sep 30, 2025$376.46M–
Q2 FY2025Jun 30, 2025$373.71M–
Q4 FY2024Dec 31, 2024$379.53M–

More Caris Life Sciences figures

See a number that looks wrong?